Keros Therapeutics, Inc.
Moat Score — Keros Therapeutics, Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Keros's foundational TGF-beta/ligand-trap IP, licensed from The General Hospital Corporation in 2016 and built out into two distinct clinical candidates, is real and differentiated enough that Takeda paid $200 million upfront for ex-China rights to elritercept alone. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a clinical-stage biotech with no approved products, Keros has no cost advantage; it is purely an R&D-spending organization funded by partnership payments and capital markets. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved, marketed product yet, Keros has no demonstrated pricing power - any future pricing power depends entirely on trial outcomes still years away. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in clinical-stage drug development - value is driven by trial data and regulatory approval, not by other users or participants. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | With no marketed product, there are no prescriber or patient switching costs to speak of yet for rinvatercept or elritercept. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Both DMD and MDS/myelofibrosis are crowded fields with a dozen or so named competitors each, suggesting these markets can support multiple players rather than rewarding Keros's current scale with exclusivity. |